Genen­tech, Blue­print tout full ap­proval for Gavre­to in rare type of lung can­cer

Genen­tech and Blue­print Med­i­cines scored a full FDA ap­proval on Wednes­day for Gavre­to’s use in a small sub­set of non-small cell lung can­cer pa­tients, near­ly three years af­ter cel­e­brat­ing an ini­tial win via the ac­cel­er­at­ed ap­proval path­way.

Gavre­to, al­so known as pralse­tinib, was ap­proved in Sep­tem­ber 2020 for adults with metasta­t­ic NSCLC with RET fu­sions, which are present in just 1% to 2% of pa­tients, the Roche sub­sidiary said at the time. Reg­u­la­tors con­vert­ed the la­bel to a full ap­proval af­ter re­view­ing sup­port­ing da­ta from 123 ad­di­tion­al pa­tients over 25 more months of fol­low-up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER